Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6686578 | 0.92 | TRPV1 (0.68) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5656769 | 0.90 | TRPV1 (0.70) | TRPV1KDM4E | |
| SCHEMBL4019256 | 0.88 | TRPV1 (0.56) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4025617 | 0.87 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL5656245 | 0.86 | TRPV1 (0.73) | TRPV1KDM4E | |
| SCHEMBL5660751 | 0.85 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL5660918 | 0.84 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL5659169 | 0.82 | TRPV1 (0.68) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5658827 | 0.82 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL5658216 | 0.81 | TRPV1 (0.72) | TRPV1KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1490340-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | TRPV1 37/4885KDM4E 3121/4885MEN1 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.